[1]Ganer Herman H, Kogan Z, Tairy D, et al. Pregnancies following hysteroscopic removal of retained products of conception after delivery versus abortion[J]. Gynecol Obstet Invest, 2018, 83(6): 586-592.
[2]The American Fertility Society. The American Fertility Society classifications of intrauterine adhesions[J]. Fertil Steril, 1988, 49(6): 944-955.
[3]Tzur Y, Berkovitz-Shperling R, Goitein Inbar T, et al. Expectant vs medical management for retained products of conception after medical termination of pregnancy: a randomized controlled study[J]. Am J Obstet Gynecol, 2022, 227(4): 599.e1-599.e9.
[4]Hooker A B, Thurkow A. Asherman’s syndrome after removal of placenta remnants: a serious clinical problem[J]. Gynecol Surg, 2011, 8(4): 449-453.
[5]Hershko Klement A, Frederic M, Bentov Y, et al. Oral contraceptive pills as an option for non-surgical management of retained products of conception—a preliminary study[J]. Gynecol Endocrinol, 2018, 34(7): 609-611.
[6]Stewart K T, Lee J S, Pan K, et al. Outcome of using vaginal misoprostol for treatment of retained products of conception after first trimester miscarriage: a retrospective cohort study[J]. Eur J Contracept Reprod Health Care, 2020, 25(6): 474-479.
[7]Nanda K, Lopez L M, Grimes D A, et al. Expectant care versus surgical treatment for miscarriage[J]. Cochrane Database Syst Rev, 2012, 2012(3): CD003518.
[8]Foreste V, Gallo A, Manzi A, et al. Hysteroscopy and retained products of conception: an update[J]. Gynecol Minim Invasive Ther, 2021, 10(4): 203-209.
[9]Ben-Ami I, Melcer Y, Smorgick N, et al. A comparison of reproductive outcomes following hysteroscopic management versus dilatation and curettage of retained products of conception[J]. Int J Gynaecol Obstet, 2014, 127(1): 86-89.
[10]Smorgick N, Mittler A, Ben-Ami I, et al. Retained products of conception: what is the risk for recurrence on subsequent pregnancies?[J]. Eur J Obstet Gynecol Reprod Biol, 2018, 224: 1-5.
[11]Hooker A B, Aydin H, Brölmann H A M, et al. Long-term complications and reproductive outcome after the management of retained products of conception: a systematic review[J]. Fertil Steril, 2016, 105(1): 156-64.e1.
[12]Incognito G G, Mac∨ek K J, Blaganje M, et al. Effectiveness of office hysteroscopy for retained products of conception: insights from 468 cases[J]. Arch Gynecol Obstet, 2025, 312(3): 791-801.
[13]Tsai N C, Hsiao Y Y, Su Y T, et al. The efficacy of early office hysteroscopy in preventing intrauterine adhesions after abortion: a randomized controlled trial[J]. BMC Womens Health, 2024, 24(1): 400.
[14]Hooker A, Fraenk D, Brölmann H, et al. Prevalence of intrauterine adhesions after termination of pregnancy: a systematic review[J]. Eur J Contracept Reprod Health Care, 2016, 21(4): 329-335.
[15]杨雪, 夏恩兰, 马宁, 等. 胚物残留的治疗现状及进展[J]. 中国医刊, 2022, 57(12): 1298-1301.
[16]张嘉怡, 杨雪, 黄晓武. 胚物残留与宫腔粘连的诊疗研究进展及相关性[J]. 中国医学创新, 2025, 22(19): 162-166.
[17]马媛媛, 王文莉, 叶红. 胚物残留并发宫腔粘连的危险因素分析[J]. 国际妇产科学杂志, 2020, 47(5): 512-515.
[18]Hooker A B, de Leeuw R, Van de Ven P M, et al. Prevalence of intrauterine adhesions after the application of hyaluronic acid gel after dilatation and curettage in women with at least one previous curettage: short-term outcomes of a multicenter, prospective randomized controlled trial[J]. Fertil Steril, 2017, 107(5): 1223-1231.e3.
[19]Hooker A B, de Leeuw R, Van de Ven P M, et al. Reproductive performance after the application of hyaluronic acid gel after dilation and curettage in women who have experienced at least one previous curettage: long-term results of a multicenter prospective randomized trial[J]. Fertil Steril, 2018, 110(7): 1231-1238.
[20]Rein D T, Schmidt T, Hess A P, et al. Hysteroscopic management of residual trophoblastic tissue is superior to ultrasound-guided curettage[J]. J Minim Invasive Gynecol, 2011, 18(6): 774-778.
[21]赵郡,张蕾, 马晓琳, 等. 宫腔粘连发病高危因素与不孕症的相关性及对临床防治的指导[J]. 临床误诊误治, 2023, 36 (7): 109-114.
[22]Wu Y F, Lu J, Lin L P. Use of anti-adhesion gel after hysteroscopy for the treatment of female infertility: a systematic review and meta-analysis[J]. Afr J Reprod Health, 2025, 29(7): 158-174.
|